The present invention relates to a novel anti-CD24 antibody and use thereof. The CD24-specific antibody according to one aspect increases phagocytosis activity of macrophages in tumor tissues, and thus can be used as a universal anticancer agent for effectively preventing or treating various cancers associated with CD24 without being limited to carcinomas, and has high binding affinity to both humans and mice, and thus can be clinically and preclinically used.
